About
About BrightPath Biotherapeutics Co., Ltd
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1223 to target blood cancers. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. The company was incorporated in 2003 and is headquartered in Kawasaki, Japan.
Visit company website
5 years, 5 months ago
BrightPath Biotherapeutics Co., Ltd is currently in a long term downtrend where the price is trading 9.0% below its 200 day moving average.
From a valuation standpoint, the stock is 1215.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 927.5.
BrightPath Biotherapeutics Co., Ltd's total revenue sank by 49.4% to $425K since the same quarter in the previous year.
Its net income has dropped by 0.7% to $-504M since the same quarter in the previous year.
Based on the above factors, BrightPath Biotherapeutics Co., Ltd gets an overall score of 0/5.